l

Home l UK Companies l Genomics Topics l Species with sequenced Genomes l Contact

l

Oxagen Ltd.

Contact Details:
Address:and Oxford Genetics Knowledge Park
Wellcome Trust Center for Human Genetics
Roosevelt Drive
Headington
Postcode:OX3 7BN
Country:UK

Loading...

Recent Publications by Oxagen Ltd.:

Novel function of CRTH2 in preventing apoptosis of human Th2 cells through activation of the phosphatidylinositol 3-kinase pathway.
It is now well established that interaction of PGD(2) with chemoattractant...
Oxagen J Immunol. 2009 Jun 15;182(12):7580-6.
DOI Direct Link
Interaction between prostaglandin D and chemoattractant receptor-homologous molecule expressed on Th2 cells mediates cytokine production by Th2 lymphocytes in response to activated mast cells.
The mechanisms by which immunologically activated mast cells stimulate the...
Clin Exp Immunol. 2009 Apr;156(1):126-33. Epub 2009 Feb 11.
DOI Direct Link
Antagonists of the prostaglandin D2 receptor CRTH2.
Prostaglandin D(2) (PGD(2)) is produced by mast cells, Th2 lymphocytes and...
Pharmacology, Oxagen Drug News Perspect. 2008 Jul-Aug;21(6):317-22.
DOI Direct Link
The roles of the prostaglandin D(2) receptors DP(1) and CRTH2 in promoting allergic responses.
Prostaglandin D(2) (PGD(2)) is produced by mast cells, Th2 lymphocytes and...
Oxagen Ltd, 91 Milton Br J Pharmacol. 2008 Mar;153 Suppl 1:S191-9. Epub 2007 Oct 29.
DOI Direct Link
A paracrine role for chemoattractant receptor-homologous molecule expressed on T helper type 2 cells (CRTH2) in mediating chemotactic activation of CRTH2+ CD4+ T helper type 2 lymphocytes.
Activation of human CRTH2(+) CD4(+) T helper type 2 (Th2) cells with...
Department of Drug Discovery, Oxagen Ltd, Abingdon, Oxon, United Kingdom. Immunology. 2007 Aug;121(4):577-84. Epub 2007 Apr 16.
DOI Direct Link

Oxagen Ltd. Patents:

US Patent No.Title
7750027 Compounds having CRTH2 antagonist activity
7582672 Compounds for the treatment of CRTH2-mediated diseases and conditions
7521194 Method for detection of MIP-4 and CCRL2 binding and activity modulating agents